|
Ricardo Dolmetsch
Richard Carl Elciario Dolmetsch (or Ricardo Dolmetsch) is a Colombian-American neuroscientist, educator and biotechnology entrepreneur. Dolmetsch is the president of Tempero Bio, a biotech company seeking to cure substance use disorders, and an adjunct professor at Stanford University. Biography and education Dolmetsch was born and raised in Cali, Colombia and attended Colegio Bolivar. He was a member of the Colombian National Track team, winning the Colombian National Championships and representing his country in both the Pan American and Junior World Championships. Dolmetsch migrated to the United States to earn a B.S. from Brown University. He obtained a doctorate in neuroscience from Stanford University in 1997 under the supervision of Richard Lewis, where he worked on the role of calcium oscillations in lymphocyte activation. He completed a postdoctoral fellowship with Michael E. Greenberg at Harvard Medical School where he studied excitation-transcription coupling, spec ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Cali, Colombia
Santiago de Cali (), or Cali, is the capital of the Valle del Cauca department, and the most populous city in southwest Colombia, with 2,227,642 residents according to the 2018 census. The city spans with of urban area, making Cali the second-largest city in the country by area and the third most populous after Bogotá and Medellín. As the only major Colombian city with access to the Pacific Coast, Cali is the main urban and economic center in the south of the country, and has one of Colombia's fastest-growing economies. The city was founded on 25 July 1536 by the Spanish explorer Sebastián de Belalcázar. As a sporting center for Colombia, it was the host city for the 1971 Pan American Games. Cali also hosted the 1992 World Wrestling Championships, the 2013 edition of the World Games, the UCI Track Cycling World Championships in 2014, the World Youth Championships in Athletics in 2015 as well as the inaugural Junior Pan American Games in 2021 and the 2022 World Athleti ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
L-type Calcium Channels
The L-type calcium channel (also known as the dihydropyridine channel, or DHP channel) is part of the high-voltage activated family of voltage-dependent calcium channel. "L" stands for long-lasting referring to the length of activation. This channel has four isoforms: Cav1.1, Cav1.2, Cav1.3, and Cav1.4. L-type calcium channels are responsible for the excitation-contraction coupling of skeletal, smooth, cardiac muscle, and for aldosterone secretion in endocrine cells of the adrenal cortex. They are also found in neurons, and with the help of L-type calcium channels in endocrine cells, they regulate neurohormones and neurotransmitters. They have also been seen to play a role in gene expression, mRNA stability, neuronal survival, ischemic-induced axonal injury, synaptic efficacy, and both activation and deactivation of other ion channels. In cardiac myocytes, the L-type calcium channel passes inward Ca2+ current (ICaL) and triggers calcium release from the sarcoplasmic reticul ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Multiple Sclerosis
Multiple (cerebral) sclerosis (MS), also known as encephalomyelitis disseminata or disseminated sclerosis, is the most common demyelinating disease, in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to transmit signals, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems. Specific symptoms can include double vision, blindness in one eye, muscle weakness, and trouble with sensation or coordination. MS takes several forms, with new symptoms either occurring in isolated attacks (relapsing forms) or building up over time (progressive forms). In the relapsing forms of MS, between attacks, symptoms may disappear completely, although some permanent neurological problems often remain, especially as the disease advances. While the cause is unclear, the underlying mechanism is thought to be either destruction by the immune system ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Ofatumumab
Ofatumumab is a fully human monoclonal antibody to CD20, which appears to provide rapid B-cell depletion. Under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the European Union and other regions. Under the brand name Arzerra, it is approved for the treatment of certain types of chronic lymphocytic leukemia (CLL) in the United States. It is sold by Novartis under license from Genmab. The most common side effects for ofatumumab (Kesimpta) include upper respiratory tract infection, headache, injection-related reactions, and local injection site reactions. The most common side effects for ofatumumab (Arzerra) include infusion reactions and neutropenia. Medical uses Ofatumumab (Kesimpta 20 mg solution for injection in pre-filled syringe/pen) is indicated for the treatment of relapsing forms of multiple sclerosis in adults. The recommended dose is 20 mg of ofatumumab administered by subcutaneous injection with ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Kesimpta
Ofatumumab is a fully human monoclonal antibody to CD20, which appears to provide rapid B-cell depletion. Under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the European Union and other regions. Under the brand name Arzerra, it is approved for the treatment of certain types of chronic lymphocytic leukemia (CLL) in the United States. It is sold by Novartis under license from Genmab. The most common side effects for ofatumumab (Kesimpta) include upper respiratory tract infection, headache, injection-related reactions, and local injection site reactions. The most common side effects for ofatumumab (Arzerra) include infusion reactions and neutropenia. Medical uses Ofatumumab (Kesimpta 20 mg solution for injection in pre-filled syringe/pen) is indicated for the treatment of relapsing forms of multiple sclerosis in adults. The recommended dose is 20 mg of ofatumumab administered by subcutaneous injection with monthl ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Migraine
Migraine (, ) is a common neurological disorder characterized by recurrent headaches. Typically, the associated headache affects one side of the head, is pulsating in nature, may be moderate to severe in intensity, and could last from a few hours to three days. Non-headache symptoms may include nausea, vomiting, and photophobia, sensitivity to light, hyperacusis, sound, or Osmophobia, smell. The pain is generally made worse by physical activity during an attack,as PDF although regular physical exercise may prevent future attacks. Up to one-third of people affected have Aura (symptom), aura: typically, it is a short period of visual disturbance that signals that the headache will soon occur. Occasionally, aura can occur with little or no headache follow ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Aimovig
Erenumab, sold under the brand name Aimovig, is a medication which targets the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine. It is administered by subcutaneous injection. Erenumab, which was developed by Amgen and Novartis, was approved in May 2018, and was the first CGRPR antagonist to be approved by the U.S. Food and Drug Administration. In 2020, it was the 234th most commonly prescribed medication in the United States, with more than 1million prescriptions. Medical uses Erenumab is indicated for the prevention of migraine in adults. Side effects Common side effects are constipation, pruritus, muscle spasms, as well as mild and mostly transient reactions at the injection site. Interactions Erenumab was shown not to interact with ethinylestradiol, norgestimate or the migraine drug sumatriptan. It is expected to generally have a low potential for interactions because it is not metabolized by cytochrome P450 enzymes. Pharmacology Me ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
MIT Technology Review
''MIT Technology Review'' is a bimonthly magazine wholly owned by the Massachusetts Institute of Technology, and editorially independent of the university. It was founded in 1899 as ''The Technology Review'', and was re-launched without "The" in its name on April 23, 1998 under then publisher R. Bruce Journey. In September 2005, it was changed, under its then editor-in-chief and publisher, Jason Pontin, to a form resembling the historical magazine. Before the 1998 re-launch, the editor stated that "nothing will be left of the old magazine except the name." It was therefore necessary to distinguish between the modern and the historical ''Technology Review''. The historical magazine had been published by the MIT Alumni Association, was more closely aligned with the interests of MIT alumni, and had a more intellectual tone and much smaller public circulation. The magazine, billed from 1998 to 2005 as "MIT's Magazine of Innovation," and from 2005 onwards as simply "published by MIT", ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Hemgenix
Etranacogene dezaparvovec, sold under the brand name Hemgenix is a gene therapy used for the treatment of hemophilia B. Etranacogene dezaparvovec is an adeno-associated virus vector-based gene therapy which consists of a viral vector carrying a gene for clotting Factor IX. The gene is expressed in the liver The liver is a major Organ (anatomy), organ only found in vertebrates which performs many essential biological functions such as detoxification of the organism, and the Protein biosynthesis, synthesis of proteins and biochemicals necessary for ... to produce Factor IX protein, to increase blood levels of Factor IX and thereby limit bleeding episodes. Hemophilia B is a Genetic disorder, genetic bleeding disorder resulting from missing or insufficient levels of blood clotting Factor IX, a protein needed to produce blood clots to stop bleeding. The most common adverse reactions include liver enzyme elevations, headache, mild infusion-related reactions and flu-like symptoms. ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
_1.jpg "Click for more on -> Migraine")